Abstract
Kanavos and Costa-Font contradict the standard arbitrage hypothesis of price competition and the race towards the bottom in the importing countries. They reject the hypothesis of price convergence among exporting and importing countries for Europe as a whole 108. Evidence from Sweden suggests that pharmaceutical companies respond to parallel traded competition by reducing their list prices, though to a level which is higher than what parallel traders are charging. Price reductions in Sweden may, therefore, have another purpose than deterring parallel trade. The reason why pharmaceutical companies reduce their list prices may, nevertheless, be parallel trade.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
P. Kanavos, J. Cost Font (2005), Economic Policy October 2005, pp 751–798
Ganslandt M and Maskus K (2004): J. of Health Economics 23 (2004) 1035–1057, p. 1049 and Ganslandt M and Maskus K (2001): Working Paper No 546, 2001, IUI, Stockholm
Cambridge Pharma Consultancy (2006), Pricing and Market Access Review, p. 8
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag AG
About this chapter
Cite this chapter
(2008). Why do prices not converge? A theoretical assessment. In: Parallel Imports of Pharmaceuticals. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8589-7_6
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8589-7_6
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8588-0
Online ISBN: 978-3-7643-8589-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)